SCHEMBL7925236

SCHEMBL7925236

Cc1nc(-c2ccccc2)n(COC(C)[Si](C)(C)C)c1CCO

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.39
HSD17B10 Q99714 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 2/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
P2RX7 Q99572 3/20 0.32
CYP1A2 P05177 2/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32
DHODH Q02127 1/20 0.32
TARBP2 Q15633 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PPARA Q07869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7923478 0.82 HSD17B10 (0.54) PPARGHSD17B10KDM4EALDH1A1HPGD
SCHEMBL7925241 0.78 ALDH1A1 (0.41) PPARGHSD17B10KDM4EALDH1A1HPGD
SCHEMBL6917978 0.71 PPARG (0.46) PPARGHSD17B10ALDH1A1HPGDP2RX7
SCHEMBL6984295 0.67 BRD4 (0.44) HSD17B10KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27850263 0.65 CYP1A2 (0.40) HSD17B10KDM4EALDH1A1NPSR1HTT
SCHEMBL9525213 0.64 ALDH1A1 (0.44) KDM4EALDH1A1L3MBTL1LMNA
SCHEMBL4838002 0.63 ALDH1A1 (0.32) KDM4EALDH1A1
SCHEMBL27850156 0.62 LMNA (0.38) HSD17B10KDM4EALDH1A1SMN1; SMN2NPSR1
SCHEMBL652738 0.62 TSHR (0.58) HSD17B10KDM4EALDH1A1HPGDNPSR1
SCHEMBL28501031 0.60 AVPR1A (0.44) ALDH1A1HPGDSMN1; SMN2HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed